Communications BiologyGenetic & Genomic MedicinePeer-reviewed journal article
Comprehensive analysis of GBA using a novel algorithm for Illumina whole-genome sequence data or targeted Nanopore sequencing
Marco ToffoliiD, Xiao Chen, Fritz Joachim SedlazeckiD, Chiao‐Yin LeeiD, Stephen MulliniD, Abigail HigginsiD, Sofia KoletsiiD, Monica Emili Garcia‐SeguraiD, Esther M. SammleriD, Sonja W. ScholziD, Anthony H.V. SchapiraiD, Michael A. EberleiD, Christos ProukakisiD
Abstract
GBA variants cause the autosomal recessive Gaucher disease, and carriers are at increased risk of Parkinsons disease (PD) and Lewy body dementia (LBD). The presence of a highly homologous nearby pseudogene (GBAP1) predisposes to a range of structural variants arising from either gene conversion or reciprocal recombination, the latter resulting in copy number gains or losses, complicating genetic testing and analysis. To date, short-read sequencing has not been able to fully resolve these or other variants in the key homology region, and targeted long-read sequencing has not previously resolved reciprocal recombinants. We present and validate two independent methods to resolve recombinant alleles and other variants in GBA: Gauchian, a novel bioinformatics tool for short-read, whole-genome sequencing data analysis, and Oxford Nanopore long-read sequencing after enrichment with appropriate PCR. The methods were concordant for 42 samples including 30 with a range of recombinants and GBAP1-related mutations, and Gauchian outperforms the GATK Best Practices pipeline. Applying Gauchian to Illumina sequencing of over 10,000 individuals from publicly available cohorts shows that copy number variants (CNVs) spanning GBAP1 are relatively common in Africans. CNV frequencies in PD and LBD are similar to controls, but gains may coexist with other mutations in patients, and a modifying effect cannot be excluded. Gauchian detects a higher frequency of GBA variants in LBD than PD, especially severe ones. These findings highlight the importance of accurate GBA mutation detection in these patients, which is possible by either Gauchian analysis of short-read whole genome sequencing, or targeted long-read sequencing.
- organism: human
- assay: whole-genome sequencing
- assay: long-read sequencing
- research focus: variant calling
- research focus: variant effect prediction
- research focus: benchmarking
- approach: statistical model
- approach: experimental assay
- Citations
- 60
- FWCI
- 6.80
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Is Gauchian genotyping of GBA1 variants reliable?
Nahid Tayebi, Jens Lichtenberg, … Ellen Sidransky·Communications BiologyPeer-reviewed·May 9, 2025
- Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinsons disease cohort
Oscar E.E. Graham, Toni L. Pitcher, … Martin Alexander Kennedy·Parkinsonism & Related DisordersPeer-reviewed·Nov 29, 2019
- GBA in Parkinson's disease: variant detection and pathogenicity scoring matters
Carolin Gabbert, Susen Schaake, … Joanne Trinh·medRxiv·Feb 3, 2023
- Accurate long-read sequencing identified GBA variants as a major genetic risk factor in the Luxembourg Parkinson's study
Sinthuja Pachchek, Zied Landoulsi, … Rejko Krüger·medRxiv·Mar 29, 2023
- Detection of GBA missense mutations and other variants using the Oxford Nanopore MinION
Melissa Leija‐Salazar, Fritz Joachim Sedlazeck, … Christos Proukakis·Molecular Genetics & Genomic MedicinePeer-reviewed·Jan 13, 2019
- The annotation and function of the Parkinson's and Gaucher disease-linked gene GBA1 has been concealed by its protein-coding pseudogene GBAP1
Emil Karl Gustavsson, Siddharth Sethi, … Mina Ryten·Science AdvancesPeer-reviewed·Jun 26, 2024